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Abstract
Objectives
Many of the cost-effectiveness analyses of apixaban against warfarin focused onWestern
populations but Asian evidence remains less clear. The present study aims to evaluate the
cost-effectiveness of apixaban against warfarin in Chinese patients with non-valvular atrial
fibrillation (NVAF) from a public institutional perspective in Hong Kong.
Methods
We used a Markov model incorporating 12 health state transitions, and simulated the dis-
ease progression of NVAF in 1,000 hypothetical patients treated with apixaban/warfarin.
Risks of clinical events were based on the ARISTOTLE trial and were adjusted with local
International Normalized Ratio control, defined as the time in therapeutic range. Real-life
input for the model, including patients’ demographics and clinical profiles, post-event treat-
ment patterns, and healthcare costs, were determined by a retrospective cohort of 40,569
incident patients retrieved from a Hong Kong-wide electronic medical database. Main out-
come measurements included numbers of thromboembolic and bleeding events, life years,
quality-adjusted life years (QALYs) and direct healthcare cost. When comparing apixaban
and warfarin, treatment with incremental cost-effectiveness ratio (ICER) less than one local
GDP per capita (USD 33,534 in 2014) was defined to be cost-effective.
Results
In the lifetime simulation, fewer numbers of events were estimated for the apixaban group,
resulting in reduced event-related direct medical costs. The estimated ICER of apixaban
was USD 7,057 per QALY at base-case analysis and ranged from USD 1,061 to 14,867 per
QALY under the 116 tested scenarios in deterministic sensitivity analysis. While in
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probabilistic sensitivity analysis, the probability of apixaban being the cost-effective alterna-
tive to warfarin was 96% and 98% at a willingness to pay threshold of USD 33,534 and
100,602 per QALY, respectively.
Conclusions
Apixaban is likely to be a cost-effective alternative to warfarin for stroke prophylaxis in Chi-
nese patients with NVAF in Hong Kong.
Introduction
Non-valvular atrial fibrillation (NVAF), the most common sustained cardiac arrhythmia,
affects 1–2% of the general population worldwide and its prevalence increases with age [1, 2].
As one of the risk factors for stroke and systemic embolism, NVAF is associated with long-
term morbidity, impaired quality of life, mortality and considerable financial burden. The
healthcare cost for patients with NVAF is estimated to increase 1.6–3.1 fold after the occur-
rence of thromboembolic events, particularly in the first three years [3]. Therefore, stroke pre-
vention in patients with NVAF is important from both individual and societal perspectives.
Long-term anticoagulation management is required for stroke prophylaxis in patients with
NVAF. Traditionally, warfarin (a vitamin K antagonist) has been the most commonly used
anticoagulant [4]. However warfarin poses challenges with respect to clinical management due
to its narrow therapeutic range and drug metabolism affected by multiple factors such as
genetic variables, diet and drug interactions[5]. Apixaban (a novel direct factor Xa inhibitor)
was therefore developed as an alternate anticoagulant. A multinational trial of ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)
demonstrated apixaban to be superior to warfarin in prevention of ischaemic stroke (21%
reduction), bleeding (31% reduction) and mortality (11% reduction) without the need for mon-
itoring [6]. Recent subgroup analysis of the landmark trial showed consistent protective effect
of apixaban on stroke, bleeding and mortality in East Asian and non-East Asian patients [7].
In addition to improved clinical efficacy and safety compared against standard treatment,
cost-effectiveness is also an important consideration for new treatments in the setting of
increased healthcare costs globally. Apixaban has been found to be cost-effective against warfa-
rin in Europe [8–10], Australia [11] and USA [12]. Notably, the current CE literature all
focused onWestern populations. Although Asians and Westerns share similar risk factor pro-
files, they might not be the same due to more history of stroke, increased tendency to bleed and
suboptimal international normalised ratio (INR) control when treated with warfarin [13].
These factors may have an impact on the cost-effective manner of anticoagulation therapies.
Hence, it is important to incorporate local data to evaluate CE in the Asian population. The
objective of the present study is to evaluate the cost-effectiveness of apixaban versus warfarin
for stroke prophylaxis in Chinese patients with NVAF, from the public institutional perspective
in Hong Kong.
Methods
The research protocol was approved by the Institutional Review Board of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster, Hong Kong. No written informed
consent was obtained from patients for their clinical records to be used in this study, due to
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this is a retrospective study based on electronic medical database. All of the patient records/
information was anonymized and de-identified prior to analysis.
Overview
This study compares the cost-effectiveness of apixaban against warfarin in Chinese patients
with NVAF using a Markov model. Data sources and the retrieval procedure are illustrated in
Fig 1. Lifetime cost and health outcomes were estimated fromMarkov cohort simulations. A
retrospective cohort study was conducted to obtain real-life data for the model inputs. Clinical
event risks were based on the ARISTOTLE trial [6] and incorporated by local INR control.
Where local data were not available, data retrieved from comprehensive literature review and
expert opinion were used. Baseline inputs are listed in Tables A and B in S1 File. Model inputs
were entered, cross-checked and analysed independently by two researchers.
Model
A previously developed Microsoft Excel Markov model incorporating 12 health states was
adapted to simulate lifetime disease progression in 1,000 patients treated by apixaban (5mg
BID) or warfarin (any strength)[14]. The health states modeled include NVAF, ischaemic
stroke, systemic embolism, myocardial infarction, bleeding and death. A simplified schematic
representation of the model structure and the health states transitions starting from NVAF are
shown in Figures A and B in S1 File. A detailed description of the model can be found in pre-
vious publications [8, 10, 15]. For each treatment group, the number of events in each health
state, life years (LYs), quality-adjusted life years (QALYs) and direct healthcare cost were calcu-
lated at the end of each model cycle and accumulated across lifetime.
Population
The target population of the model are patients with NVAF who are suitable for warfarin ther-
apy. Patient profiles were determined by a retrospective cohort analysis of incident patients
with NVAF in the Clinical Data Analysis and Reporting System (CDARS). In brief, CDARS is
an electronic medical database in Hong Kong that covers a population of over 7 million utilis-
ing public healthcare services and accounts for 80% of inpatient records in the territory [16].
De-identified electronic patients’ records, including demographics, diagnoses, procedures,
drug descriptions, laboratory tests and date of consultation, hospital admission and discharge,
were all imported to CDARS for audit and research purposes.
At the time of the study, CDARS was unable to identify patients with NVAF directly. Target
patients were identified by first retrieving patients with documented diagnosis of atrial fibrilla-
tion from Jan 1st 2010 to Dec 31st 2013 using ICD-9 diagnosis codes (Table C in S1 File for
ICD-9 codes used). Among these patients, those with diagnoses of valvular heart disease,
hyperthyroidism or had undergone valvular replacement surgery within 1 year prior to the
index date were further excluded according to corresponding ICD-9 codes. The follow-up of
each patient was commenced from the index date until the occurrence of any clinical events,
death or July 31st 2014, whichever came first. This resulted in the identification of 40,569 eligi-
ble patients with 76,196 patient-years of follow-up. The key demographic and clinical profiles
of these patients are shown in Table 1.
Risk of clinical events
The clinical event rates of apixaban and warfarin were obtained from the ARISTOTLE trial [6].
As the risk of ischaemic stroke and bleeding associated with warfarin are highly dependent on
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the quality of INR control [17, 18], the model was developed to adjust the event risks by local
INR control. Time in therapeutic range (TTR) distribution was defined as the indicator of INR
control and collected from the CDARS retrospective cohort study.
Fatality and mortality
For thromboembolic and bleeding events, annual case-fatality rates were estimated from the
CDARS retrospective cohort study. All-cause mortality was modelled based on life tables in the gen-
eral population, adjusting by age, gender and the occurrence of NVAF and relevant co-morbidities.
Anticoagulation management
Healthcare resource consumption regarding anticoagulation management was reflected by the
frequency of routine care and monitoring visits, proportion of patients experiencing dyspepsia
Fig 1. Data sources for Markov cohort simulation. ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation; CDARS: Clinical Data Analysis and Reporting System of Hong Kong; NVAF: non-valvular atrial
fibrillation.
doi:10.1371/journal.pone.0157129.g001
Table 1. Demographic and clinical profiles of patients with NVAF in CDARS 2010–13.
Characteristics
Sample size 40,569
Demographics
Age [median (interquartile range)] 78.9 (69.7–85.6)
Female sex (%) 50.4
Medical history
Prior myocardial infarction (%) 9.2
Prior clinically relevant bleeding (%) 19.3
Prior stroke, transient ischaemic attack, or systemic embolism (%) 20.6
Heart failure or reduced left ventricular ejection fraction (%) 25.3
Diabetes (%) 22.2
Hypertension requiring treatment (%) 76.0
CHADS2 score*
Distribution (%)
0–1 41.6
2 24.0
3 34.4
Mean (SD) 2.0 (1.5)
TTR distribution (%) †
TTR < 52.38% 61.3
52.38% TTR < 66.02% 18.1
66.02% TTR < 76.51% 9.0
TTR 76.51% 11.6
Anticoagulation management,monitoring and routine care
Frequency of INR monitoring (number/month) 1.0
Patients experiencing dyspepsia whilst on warfarin (%) 0.4
Patients requiring annual renal monitoring while on warfarin (%) 29.7
* CHADS2: congestive heart failure, hypertension, age75 years, diabetes mellitus and stroke
† TTR: time in therapeutic range estimated using the Rosendaal method.
doi:10.1371/journal.pone.0157129.t001
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and proportion of patients requiring annual renal monitoring whilst on treatment from the
CDARS retrospective cohort (Table A in S1 File).
Treatment pattern post-events
Treatment patterns post-event were determined from the CDARS retrospective cohort study,
published literature or expert opinion wherever appropriate (Table A in S1 File). Following all
bleeding events, a certain number of patients were assumed to switch to aspirin as second line
treatment. The rate of treatment switch (± 90 days of the event index date) was determined by
retrieving prescription records from CDARS and literature. The remaining patients were mod-
elled to have their original treatment interrupted for 6 weeks then restarted [19] (i.e. as shown
in Table A in S1 File, post intracranial haemorrhage, 44% of patients switched to aspirin and
the remaining 56% discontinued their original treatment temporarily and restarted the same
treatment 6 weeks later). [20]Following occurrence of ischaemic stroke and systemic embolism,
all patients were assumed to continue the original treatment as advised by experts.
Utility
Utility for NVAF was adopted from Ho et al [21], which was the only study to assess the health
utility of Hong Kong patients with NVAF on oral anticoagulants. Due to the absence of popu-
lation-specific utility estimations, a UK-based utility catalogue was adopted for other health
states [22]. Marginal disutility was assumed to be associated with INR monitoring when treated
with warfarin due to the required blood test [23]. All utility inputs were discounted at 3.5% per
year and detailed in Table B in S1 File.
Cost
The analysis was conducted from a public institutional perspective in Hong Kong so only direct
medical costs were considered. Costs are presented to the value of US dollars in 2014 (1 USD
to 7.75 HKD) and discounted at 3.5% per year according to cost-effectiveness analyses (CEA)
guideline [24].
The total cost components are outlined in Table B in S1 File. Daily drug costs for warfarin
and apixaban were based on local retail prices (internal communication with Bristol-Myers
Squibb, Hong Kong, November 2014). Annual monitoring and management costs were deter-
mined by multiplying the cost for blood and renal tests per visit by number of clinical visits per
patient from the CDARS retrospective cohort. Similarly, acute care costs associated with clini-
cal events were calculated by multiplying daily inpatient charges in public hospital [25, 26] by
the average hospital length of stay estimated from the same cohort. Long-term care costs
include medication costs only.
Analyses
We compared the cost-effectiveness of apixaban versus warfarin by assessing the differences in life-
time cost and clinical benefits. Base-case analysis was performed based on model inputs described
earlier. Treatment with incremental cost-effective ratio (ICER) less than the willingness-to-pay
(WTP) threshold of one local GDP per capita (USD 33,534 in 2014 [27]) for each QALY gained
was considered a cost-effective alternative as recommended by theWHO-CHOICE guideline [28].
The effect of uncertainties in the base-case analysis was evaluated by deterministic and
probabilistic sensitivity analyses (SA). In deterministic SA, each of the 116 input parameters
varied from a predefined range (95% CI or SD, as listed in Tables A and B in S1 File) while all
the others were constant to project its effect on ICER. All tested parameters were ranked
Cost-Effectiveness Analysis of Apixaban vsWarfarin
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according to ICER variation and the top 15 most influential parameters were presented in Tor-
nado diagrams.
In probabilistic SA, probability distributions were assigned to each parameter (gamma dis-
tribution to event rates, beta distribution to utilities and log-normal distribution to cost) and
varied simultaneously in 2,000 iterations for the pair-wise comparisons. The cost and health
outcomes were further assessed using cost-effectiveness acceptability curves (CEACs). Two
willingness-to-pay (WTP) thresholds, one-time and three-times of local GDP per capita (USD
33,534 and USD 100,602 in 2014 [27]) were applied to explore the proportion of acceptable tri-
als for each treatment.
Results
Base-case analysis
From a cohort of 1,000 patients over a lifetime, the use of apixaban was predicted to result in 116
fewer NVAF-related events (12 fewer ischaemic strokes, 15 fewer haemorrhagic strokes, 12 fewer
other intracranial haemorrhages, 25 fewer other major bleeds, 2 fewer myocardial infarctions)
and 31 fewer event-related deaths than patients treated with warfarin in the base-case analysis
(Table 2). Compared with warfarin, 36 patients need to be treated with apixaban to avoid one
additional stroke, and apixaban is the dominant treatment in reducing bleeding events.
The cost of treating one patient with apixaban was USD 1,228 more than warfarin
(Table 2). This was predominantly attributed to the higher drug price of apixaban, in contrast
to lower costs related to management, monitoring and clinical events. Compared with warfa-
rin, the net cost, net health benefits and incremental cost-effective ratios of apixaban were
detailed in Table 3.
Deterministic sensitivity analyses
As illustrated in Fig 2, tested model inputs had limited impact on the ICER. The ICER ranged
from USD 1,061 to 14,867 per QALY gained under 116 tested scenarios, all of which were
within the threshold of USD 33,534 per QALY (one local GDP per capita). Uncertainties in
drug costs, the risk of cardiovascular hospitalisation for both treatments, risk of ischaemic
stroke for apixaban and risk of intracranial haemorrhage for warfarin had greatest impact on
the ICER.
Probabilistic sensitivity analyses
The probabilistic sensitivity analysis demonstrated that apixiban is more cost-effective against
warfarin over a life-time horizon (Fig 3). ICER was below the threshold of USD 33,534 per
QALY (one local GDP per capita) in 96% of the trials. When the upper range of the WHO
threshold of USD 100,602 per QALY gained (three-times of local GDP per capita) was applied,
98% of the trials supported the cost-effectiveness of apixaban.
The uncertainties in the cost-effective estimates are further summarised in the cost-effec-
tiveness acceptability curve in Fig 4. This demonstrates that apixaban was a superior treatment
choice representing the maximum net benefit over warfarin, when payers are willing to pay
USD 7,500 or above for one QALY gained.
Discussion
Summary of findings
In this study, our principal findings were as follows: (i) fewer thromboembolic events were esti-
mated for the apixaban group in the lifetime cohort simulations, resulting in corresponding
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increased LYs, QALYs and reduced event-related healthcare costs; (ii) compared with warfarin,
apixaban presented an ICER of USD 1,061–14,867 per QALY gained which is within the com-
mon acceptable WTP of one local GDP per capita as recommended by the WHO[28]; (iii)
Table 2. Health and cost outcome estimations in base-case analysis.
Apixaban Warfarin Difference (apixaban–warfarin)
Number of events (per cohort of 1000)
Ischaemic stroke 179 191 -12
Haemorrhagic stroke 21 36 -15
Systemic embolism 17 18 -1
Other intracranial haemorrhage 9 21 -12
Other major bleeds 106 131 -25
Clinically relevant non-major bleeds 190 239 -49
Myocardial infarction 62 64 -2
Total number of events 584 700 -116
Death (per cohort of 1000)
Event related death 268 299 -31
Other deaths 732 701 31
Health outcome (per patient)
Life years 6.84 6.67 0.17
Quality adjusted life years 5.06 4.88 0.18
Cost components (USD per patient)
Anticoagulant 3,239 379 2860
Monitoring and management 64 885 -821
Clinical events
Ischaemic stroke 2,872 3,121 -249
Haemorrhagic stroke 317 560 -243
Systemic embolism 319 330 -11
Other intracranial haemorrhage 31 75 -44
Other major bleeds 503 661 -158
Clinically relevant non-major bleeds 677 869 -192
Myocardial infarction 376 393 -17
Other cardiovascular hospitalisation 3,928 3,825 103
Total event cost 9,023 9,834 -811
Total lifetime cost 12,326 11,098 1,228
doi:10.1371/journal.pone.0157129.t002
Table 3. Base-case cost-effectiveness analysis.
Evaluated items Apixaban vs. Warfarin
Net cost (USD per patient) 1,228
Net QALYs (per patient) 0.18
Net life-years (per patient) 0.17
Incremental cost per QALY gained (USD/QALY) 7,057
Incremental cost per life year gained (USD/LY) 7,181
Incremental cost per stroke avoided (USD/stroke avoided)* 45,481
Incremental cost per bleed avoided (USD/bleed avoided) † 23,615
* Stroke included ﬁrst-ever and recurrent ischaemic and haemorrhagic strokes
† Bleed included ﬁrst-ever and recurrent haemorrhagic stroke, other intracranial haemorrhage and other
major bleeds.
doi:10.1371/journal.pone.0157129.t003
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both deterministic and probabilistic sensitivity analyses support the cost-effectiveness of apixa-
ban over a range of uncertainties. This study utilises the strength of CDARS, which collects
clinical data in the public healthcare setting across the whole territory. As far as we are aware,
this is the only study which utilises real-life, Hong Kong-specific cost, patient demographics
and clinical profiles, treatment patterns and case fatality rates to compare the cost-effectiveness
of apixaban versus warfarin.
The greater health benefits and cost-effectiveness of apixaban findings in this study are in
line with other modeling CE studies conducted in western developed countries [8–12]. Lee et al
demonstrated apxiaban as a dominant strategy (both cost and life year savings) from the US
Medicare perspective [12], while the remaining four studies all found apixaban more cost-
effective against warfarin in Australia, Netherlands, Sweden and United Kingdom at ICERs of
AUD 13,679[11], EUR 10,576[8], SEK 33,458[9], GBP 11,909[10] per QALY respectively,
applying locally relevant WTP thresholds.
Asian data
In light of the widely reported cost-effectiveness of apixaban in Caucasians, evaluation of the
Asian population is still limited. However, from a clinical perspective, Asian and Western
patients with AF are not necessarily the same. Firstly, among the five components of the
CHADS2 (congestive heart failure, hypertension, age75 years, diabetes mellitus and stroke)
score, similar risk factor profiles were shared, except previous stroke is more prevalent in
Asians (29% vs. 18%) [13]. Secondly, stroke risk is higher in Asians when treated with warfarin
as reflected in the subgroup analysis of ARISTOTLE trial (3.4% vs. 1.4%) [6, 7]. Thirdly, despite
Fig 2. Tornado diagram of apixaban versus warfarin.
doi:10.1371/journal.pone.0157129.g002
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a lower INR in general, warfarin users in Asia are more likely to bleed than non-Asians (3.8%
vs. 3.0%) [6, 7]. Although the mechanism for these differences remains to be determined, they
may all challenge the proper use and cost-effectiveness of warfarin and its alternatives in Asia.
For the first time, our analysis showed that apixaban is cost-effective in a Chinese population.
This is an important ethnic group in Asia with a high prevalence of stroke [29] and rapidly
increasing ageing population [30], which highlights the prominence of this study.
Real-life data
Another important differentiator and strength of our study is the use of real-life, local INR con-
trol data in our model. It is well documented in the published literature that good INR control,
although important for good clinical outcome [31], is unusual in both clinical trial [32] and
real-life settings [33]. The ARISTOTLE trial reported that only 50% of warfarin patients have
TTR 66.0% [6]. Hong Kong practice is not an exception. Consistent with our findings from
the CDARS retrospective cohort study, which found a median TTR of 40.9%, Ho et al also
reported unsatisfactory INR control among patients in Hong Kong with similar TTR (median:
38.8%) [33]. As TTR is negatively correlated with bleeding and thromboembolic events [34],
suboptimal INR control in real-life may worsen the performance of warfarin [35]. Potential
health benefits offered by apixaban may be greater than that in the clinical trial setting for
Fig 3. Probabilistic sensitivity analysis of apxiaban versus warfarin.
doi:10.1371/journal.pone.0157129.g003
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patients with poor TTR [13] when compared to warfarin. By incorporating real-life INR control
for event risks adjustment, our study provides a more realistic picture compared to previous stud-
ies where the risks were based on clinical trials [11, 12] or tested in scenario analyses [9, 10].
Of note, variations in healthcare system and services have been well recognised worldwide
[36] and this is another key reason why country-specific CEA needs to be conducted. This
study summarised local relevant information and will contribute to anticoagulation policy con-
sideration in Hong Kong and other Asian countries with similar healthcare systems.
Limitations
There are limitations in this modeling analysis. Firstly, clinical efficacy and safety parameters
were based on the landmark trial with 1.8 years of follow-up. They were assumed to be constant
over the lifetime in the model, but might not reflect the long-term performance of treatments
in real terms. Secondly, following a major bleeding event, treatment options were limited to
switching to aspirin or restarting the original anticoagulant in 6 weeks. In real-life clinical prac-
tice, some patients may cease treatment or choose other anticoagulants. However, aspirin is
perceived as a safer alternative to oral anticoagulants in the Chinese population [20] given the
Fig 4. Cost-effectiveness acceptability curves of apixaban and warfarin.
doi:10.1371/journal.pone.0157129.g004
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particular concerns of increased bleeding risk among the Chinese [37–40]. As indicated in our
previous work [41], more than twice the number of NVAF patients was receiving antiplatelet
drugs including aspirin, compared to oral anticoagulants in Hong Kong, despite having a
higher risk of stroke (CHADS22). In addition, the cut-off point of assessing treatment switch
was restrict to 90 days, based on Witt et al’s study on the association of warfarin interruption
and gastrointestinal tract bleeding [42]. This may be arbitrary as there are no published guide-
lines on the optimal anticoagulation approach for those experiencing a thromboembolic event
at the time our study was conducted [43]. Thirdly, in the baseline analysis, we optimistically
assumed no renal monitoring was required for patients on apixaban based on the subgroup
analysis of ARISTOTLE [44] which may not be the case in real clinical practice. The subgroup
analysis was pre-specified for patients with impaired renal function and showed that apixaban
was more effective than warfarin in preventing stroke or systemic embolism and reducing mor-
tality, irrespective of renal function. Considering the median age of 78.9 years in this cohort of
patients, we analysed two other scenarios—assuming 50% and 100% of patients will have their
renal function evaluated annually, respectively, whilst on apixaban. Both scenarios show that
the frequency of renal monitoring had very limited impact on the ICERs (USD 7,270 and USD
7,482 per QALY saved respectively) therefore baseline conclusions remains robust. Fourthly,
treatment attributes such as convenience of drug administration, food and drug interaction
were not included in this model, which may underestimate the benefits of apixaban. Lastly, the
estimate for acute event cost per episode was restricted to general ward charges only and the
costs of emergency and intensive care or rehabilitation have not been included. These would
have led to underestimates of event related costs for both groups.
Conclusion
In conclusion, the current comprehensive modeling assessment based on real-life, local clinical,
economic evidence and ARISTOTLE trial, demonstrate that apixaban is a cost-effective alter-
native against warfarin for the prevention of stroke and bleeding events in Chinese patients
with NVAF. Our results suggest that apixaban is relatively more favourable in terms of health
benefits and incremental cost.
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